Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RxElite signs supply and marketing agreement with Hi-Tech Pharmacal
Under the terms of the agreement, RxElite will be responsible for the exclusive US supply of active pharmaceutical ingredient to be used in the manufacture of the generic
Under the terms of the agreement, RxElite will be responsible for the exclusive US supply of active pharmaceutical ingredient to be used in the manufacture of the generic
Roxane Laboratories’s Morphine sulfate CII is available in 15mg, 30mg tablet strengths and 10mg/5ml, 20mg/5ml oral solution strengths. Roxane Laboratories’s Morphine sulfate tablets and oral solutions CII are
The purpose of the study will be to demonstrate safety and monitor viral load changes in patients who are not yet eligible for antiviral drug therapy. Energex Systems’s
This randomized, double-blind, placebo-controlled Phase III trial is designed to evaluate the efficacy and safety of MAP0004 in treating acute migraine. The primary efficacy endpoints will be pain
Lumedx’s CardioPACS 5.0 is said to be a next generation PACS solution that offers new and better ways to manage images and data with a fully integrated suite
NovaBone, a calcium-phosphate silicate, is said to be the only synthetic that is osteostimulative, directly increasing the proliferation and activity of osteoblasts, the cells responsible for new bone
Most of the money was spent on fees, travel expenses, and other direct payments to Vermont physicians, hospitals, universities and others for the purpose of marketing their products.
The patent at issue was granted to Angiotech Pharmaceuticals by the European Patent Office on June 25, 1997. However, five different companies opposed the patent and the UK
The OSEO award will provide partial funding for the hepatitis C virus (HCV) clinical development program of the company’s lead product, recombinant human Interleukin-7 (r-hIL-7), a critical growth
The transaction was co-led by Deerfield Management and Intel Capital, Intel’s global investment organization. Other new investors included – Morgan Stanley, Redmile Group, T Rowe Price, and a